Lyell Immunopharma (NASDAQ:LYEL) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Lyell Immunopharma's stock received a "Sell (D-)" rating from Weiss Ratings, indicating a negative outlook from analysts.
• The company recently reported earnings of ($2.89) per share, beating analysts' expectations of ($3.80) by $0.91.
• Institutional investors have significantly increased their holdings in Lyell Immunopharma, with AQR Capital Management raising its stake by 773.5% in the first quarter.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by stock analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

LYEL has been the topic of a number of other reports. HC Wainwright restated a "neutral" rating and issued a $10.00 price target on shares of Lyell Immunopharma in a research report on Tuesday, June 24th. Wall Street Zen upgraded shares of Lyell Immunopharma from a "sell" rating to a "hold" rating in a research report on Monday, September 1st. One equities research analyst has rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Lyell Immunopharma has a consensus rating of "Sell" and a consensus price target of $15.00.

Lyell Immunopharma Stock Up 3.2%

NASDAQ LYEL opened at $18.26 on Wednesday. The stock has a market cap of $350.79 million, a P/E ratio of -0.75 and a beta of -0.07. The company's 50-day simple moving average is $12.59 and its 200 day simple moving average is $10.55. Lyell Immunopharma has a twelve month low of $7.65 and a twelve month high of $30.00.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($2.89) earnings per share for the quarter, beating analysts' consensus estimates of ($3.80) by $0.91. The business had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. Lyell Immunopharma had a negative net margin of 552,328.31% and a negative return on equity of 85.58%. Research analysts anticipate that Lyell Immunopharma will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

Institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC raised its stake in shares of Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock worth $94,000 after buying an additional 154,327 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Lyell Immunopharma during the second quarter worth approximately $94,000. Exchange Traded Concepts LLC raised its stake in shares of Lyell Immunopharma by 82.4% during the first quarter. Exchange Traded Concepts LLC now owns 246,349 shares of the company's stock worth $133,000 after buying an additional 111,299 shares during the last quarter. Bridgeway Capital Management LLC bought a new stake in shares of Lyell Immunopharma during the second quarter worth approximately $159,000. Finally, Walleye Capital LLC bought a new stake in shares of Lyell Immunopharma during the second quarter worth approximately $258,000. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.